Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures (TALSLB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05137665|
Recruitment Status : Recruiting
First Posted : November 30, 2021
Last Update Posted : October 20, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Amyotrophic Lateral Sclerosis Movement Disorders Degenerative Disorder Motor Neuron Disease|
An industry wide survey performed by Dr. Lyle Ostrow at Johns Hopkins University indicated that longitudinal bio-fluids linked to detailed clinical information are critical to continued drug development for amyotrophic lateral sclerosis (ALS), with CSF being the top biofluid often lacking in longitudinal sample biorepositories. There have been prior efforts for longitudinal collection of biofluids matched to clinical information (see https://cdmrp.army.mil/alsrp/resources/Biorepositories_biofluids_celllines for a listing of ALS biorepositories), but those sample sets are limited in size and quickly utilized by the research community. Based upon input from industry leaders, we propose the creation of a Target ALS longitudinal biofluids biorepository linked to patient genetic and clinical information.
Given the heterogeneous clinical and biologic nature of ALS, a repository of longitudinal samples linked to clinical and genetic information is essential to help identify and verify ALS biomarkers. Recent studies to identify ALS biomarkers have used longitudinal samples from either the sporadic patient population or from those that harbor genetic mutations known to cause ALS but are not yet symptomatic. Beyond exploring the relationship between known causative genes and candidate biomarkers, the Target ALS Postmortem Core has collected postmortem ALS tissue samples linked to whole genome sequencing information that have been valuable at finding new subtypes of ALS linked to transcriptomics profiles from the tissue samples. The current study utilizes medical centers participating in the Target ALS Postmortem Core to create a longitudinal biofluids repository from living patients and healthy controls. Given the impact of COVID-19 on ALS clinical research studies and clinical trials, all participants will participate in at home speech measures on a weekly basis and we will also enroll 100 ALS and 30 healthy control participants for at home measures of vital capacity that are completed once every two weeks. The added feature of these at home measures is to further evaluate the potential for at home measures in future clinical trials and ability to obtain enriched speech and vital capacity measures to correlate to downstream biomarker studies using biofluid or genetic data. There is a growing interest in the use of at home speech analytics to classify and monitor ALS patients, with recent studies indicating the value for these at home measures in both clinical research and clinical trial settings. Our study will not only expand upon these early findings but also include at home spirometry measures of vital capacity to evaluate the ability to obtain reliable vital capacity measures at home.
Our proposed study will provide valuable longitudinal biofluids linked to clinical information, genetic data, at home speech and vital capacity measures for use in future research studies. These de-identified samples and clinical information will be available to investigators throughout the world to enhance ALS research and ultimately improved treatments for ALS. There is a long history of benefit for biorepositories with linked clinical data to be instrumental in research progress. Most studies that identify biomarkers or validate biomarkers for human diseases typically require banked samples that are linked to clinical information to determine sensitivity/specificity of the biomarker for that disease or to demonstrate change over course of disease.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||280 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At - Home Measures|
|Actual Study Start Date :||January 1, 2021|
|Estimated Primary Completion Date :||December 2026|
|Estimated Study Completion Date :||December 2026|
Amyotrophic Lateral Sclerosis ALS
Amyotrophic Lateral Sclerosis (ALS): Clinical diagnosis of ALS requires the presence of UMN and LMN involvement in different body regions and evidence of progressive spread of symptoms or signs according to EEC. ALS clinic patients with suspected, possible, probable, probable-laboratory supported, or definite ALS will be included. ALS clinic participants with suspected, possible, probable, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC) will participate in 5 longitudinal visits; Screening/Baseline Visit 1, and four (4) follow-up visits which will occur at approximate 4-month intervals. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
Healthy participants (family or friends) will have a neurologic exam to confirm non-neurologic disease status and will participate in 2 longitudinal visits; Screening/baseline Visit 1, and one (1) follow-up which will occur at approximate 12-month interval. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
- Biofluid Biorepository [ Time Frame: + 3.5 Years ]This project will create a biorepository of longitudinal biofluid samples, linked to clinical measures, and at home measures
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
Inclusion ALS participants:
- Age 18 or older.
- Ability to understand the purpose and risks of the study, provide informed consent and comply with trial procedures.
- Diagnosis of ALS according to revised EEC, including suspected, possible, probable (+/- laboratory supported), and definite.
- Vital capacity (VC) at least 50% predicted value for gender, height and age at screening
- In the opinion of the study physician, able to tolerate study procedures, including lumbar puncture, for the duration of the study.
- A Score of 2 or more on item one (SPEECH) of the ALSFRS-R scale.
- Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator 15 (i.e.: no bleeding disorder, allergy to local anesthetics, a skin infection at or near the LP site, or evidence of high intracranial pressure).
- Access to a smartphone or tablet, and internet access at home.
Inclusion Healthy participants:
- Age 18 or older.
- Capable of providing informed consent and complying with trial procedure.
- No history of neurological disease, as determined by the investigator.
- Individuals that harbor known genetic mutations that cause ALS yet are asymptomatic can also be enrolled in the Healthy participant cohort.
- Access to a smartphone or tablet, and internet access at home.
Exclusion ALS and Healthy participants:
- Any known or suspected abnormal CSF pressure or intracranial/intraspinal tumors
- Use of anticoagulant medication (eg. warfarin, dalteparin, enoxaparin, rivaroxaban, fondaparinux, dabigatran) that cannot be safely withheld until coagulation parameters have normalized prior to lumbar puncture and for up to a week following the lumbar puncture.
- Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.
- Clinical judgment of the Site Investigator that the participant would be unable to undergo multiple lumbar punctures.
- Inability to perform at home speech measures using an app on a patient device (phone or iPad)
Individuals participating in other clinical research studies will be eligible to participate in this study. ALS patients on any currently approved therapies (riluzole, edaravone) are eligible to participate and continue their medications throughout this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05137665
|Contact: Manish Raisinghani, MBBS PhDfirstname.lastname@example.org|
|Contact: Robert Bowser, PhDemail@example.com|
|United States, Arizona|
|Barrow Neurological Institute||Recruiting|
|Phoenix, Arizona, United States, 85013|
|Contact: Whitney Dailey, MS 602-406-7804 ext 67804 firstname.lastname@example.org|
|Contact: Lisa Butler, MPH 602-406-4217 ext 64217 email@example.com|
|Principal Investigator: Shafeeq Ladha, MD|
|United States, California|
|University of California San Diego||Recruiting|
|San Diego, California, United States, 92121|
|Contact: Gil Gutierrez 858-246-2325 firstname.lastname@example.org|
|Principal Investigator: John Ravits, MD|
|United States, District of Columbia|
|Georgetown, District of Columbia, United States, 20007|
|Contact: Chris Gough email@example.com|
|Contact: Sarai Bartlett 202-444-6941 firstname.lastname@example.org|
|Principal Investigator: Brent Harris, MD|
|United States, Florida|
|Jacksonville, Florida, United States, 32224|
|Contact: Alexander Burch 904-953-4724 email@example.com|
|Principal Investigator: Bjorn Oskarsson, MD|
|United States, Missouri|
|Saint Louis, Missouri, United States, 63110|
|Contact: Jeri Oranski 314-362-9895 firstname.lastname@example.org|
|Contact: Jesse Markway 314-747-7881 email@example.com|
|Principal Investigator: Tim Miller, MD|
|Principal Investigator: Cindy Ly, MD|
|United States, New York|
|New York, New York, United States, 10032|
|Contact: Ben Hoover 717-649-4241 firstname.lastname@example.org|
|Contact: Vivien Garcia email@example.com|
|Principal Investigator: Neil Schneider, MD|
|Sub-Investigator: Matt Harms, MD|
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19140|
|Contact: John Furey firstname.lastname@example.org|
|Principal Investigator: Terry Heiman-Patterson, MD|
|Study Director:||Manish J Raisinghani, MBBS PhD||Target ALS Foundation, Inc.|
|Responsible Party:||Target ALS Foundation, Inc.|
|Other Study ID Numbers:||
|First Posted:||November 30, 2021 Key Record Dates|
|Last Update Posted:||October 20, 2022|
|Last Verified:||October 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.
It is expected to take approximately 5 years to complete all sample and data collection for the study. The first phase of the study will involve activating all sites participating in the study, and will take about 4 months to complete. The enrollment period is expected to be about 2-3.5 years. Active assessment for each subject will be for 16-18 months from the time of enrollment. After the end of active assessment period (5 years), the bio-samples and clinical information from the study will be made available for future research.
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
|Time Frame:||Greater than 5+ Years|
|Access Criteria:||Access available using published manuscripts and stored biofluids using the BioLims Repository.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Amyotrophic Lateral Sclerosis
ALS Amyotrophic Lateral Sclerosis
Barrow Neurological Institute
New York Genome Center
Genomic-wide association studies
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Spinal Cord Diseases
Central Nervous System Diseases